The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 02, 2021
Filed:
May. 26, 2017
Applicant:
Genea Biocells Usa (Holdings), Inc., San Diego, CA (US);
Inventors:
Amanda Rickard, San Diego, CA (US);
Anabel De La Garza, San Diego, CA (US);
Uli Schmidt, San Diego, CA (US);
Alexander Kiselyov, San Diego, CA (US);
Assignee:
Sonic Master Limited, Tortola, VG;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61P 21/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/52 (2006.01); A61K 31/551 (2006.01); G01N 33/50 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01); A61K 31/706 (2006.01); A61K 31/4412 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/4412 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/52 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/706 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01); G01N 33/5023 (2013.01); G01N 33/5061 (2013.01);
Abstract
Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.